Business Wire

Booking.com and Antom Partner to Expand Local Payment Options Across Asia

15.1.2025 05:47:00 EET | Business Wire | Press release

Share

Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/

This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partnerships and deep knowledge of local payment landscapes.

Antom has established local acquiring capabilities in over 40 countries and regions, enabling businesses to integrate hundreds of payment methods and supports transactions in over 100 currencies. It offers businesses seamless access to a diverse range of global payment options, including credit cards, e-wallets, and local payment solutions. By leveraging AI technology, Antom helps merchants enhance transaction security, optimise foreign exchange risk management, reduce costs, and improve operational efficiency through real-time payments and blockchain solutions. Additionally, Antom provides digitisation and digital marketing solutions to support merchants’ business growth.

Booking.com is committed to making it easier to experience the world, with a smooth and seamless payment process being a key factor in enabling travellers to book with ease and confidence. Through its partnership with Antom, the digital travel platform will make over 40 payment options available over time, including online banking, bank transfers, digital wallets and local card payments. Key mobile wallets such as AlipayHK (Hong Kong SAR, China), Boost (Malaysia), GCash (the Philippines), GrabPay (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Touch 'n Go eWallet (Malaysia) and TrueMoney (Thailand) will be the first to be introduced as new payment methods. This added flexibility empowers a wider range of customers to use their preferred payment methods, streamlining the checkout process and ensuring quicker, more seamless transactions - ultimately unlocking travel opportunities for more consumers across Asia Pacific.

By integrating Antom’s multi-currency offerings and cross-border settlement capabilities, Booking.com is empowering its global accommodation providers to expand user reach, and optimise payment acceptance and reconciliation across diverse markets. This collaboration will especially benefit smaller properties and holiday rentals that may lack access to traditional payment infrastructures, enabling them to compete more effectively in the global marketplace.

Daniel Marovitz, Senior Vice President of Fintech, at Booking.com commented, "Partnering with Antom allows us to streamline and enhance the payment experience for our travellers across Asia Pacific, integrating a wider range of local payment options that align with regional preferences. This collaboration reflects our commitment to delivering a seamless travel experience from booking to checkout. We look forward to working with Antom to support local businesses and continue advancing a more connected, innovative payment ecosystem for travel."

“We’re excited to partner with Booking.com to expand payment options, broaden customer reach across diverse markets, and support the platform in better serving the unique needs of each region,” said Gary Liu, General Manager of Antom, Ant International. “This partnership reflects our commitment to making payments more efficient and enabling merchants to unlock new growth opportunities in today’s dynamic landscape.”

About Booking.com
Part of Booking Holdings Inc. (NASDAQ: BKNG), Booking.com’s mission is to make it easier for everyone to experience the world. By investing in the technology that helps take the friction out of travel, Booking.com’s marketplace seamlessly connects millions of travellers with memorable experiences every day. For more information, follow @bookingcom on social media or visit globalnews.booking.com.

About Antom
Ant International’s Antom is the leading payment and digitisation services provider for merchants around the world. It offers one-stop, vertical-specific digital payment solutions to meet the payment needs of merchants of all sizes. Antom has established local acquiring capabilities in over 40 markets, with the flexibility to accept payments in more than 100 currencies. It also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers. To learn more, please visit https://www.antom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114445080/en/

Contacts

Media

Booking.com
Allison Worldwide
E: sg-booking@allisonworldwide.com
M: (65) 9130 3535

Ant International
Janice Chen
E: janicechen.cyh@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye